Bharat Biotech in tie-up with the US-based company FluGen and University of Wisconsin Madison to develop a vaccine named “Coro-Flu” to fight against COVID-19. CoroFlu will build on the backbone of FluGen’s flu vaccine candidate known as M2SR.
The vaccine is being developed on the basis of FluGen’s flu vaccine candidate known as M2SR, a self-limited version of the influenza virus. It induces an immune response against the flu. The vaccine will be built by FluGen’s lab that inserts gene sequences from SARS-CoV-2, the novel coronavirus that causes the disease COVID-19 into M2SR so that the novel vaccine will also induce immunity against the coronavirus.
Important takeaways for all competitive exams:
- Headquarters of Bharat Biotech: Hyderabad,Telangana.
- Chairman and Managing Director of Bharat Biotech: Krishna M Ella.